Codiak Biosciences: Funding, Investors & Team (Sep 2026)
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Codiak Biosciences has raised $22.5M across 2 funding rounds on record, the most recent a Post-IPO Equity of $20.0M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Codiak Biosciences Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Codiak Biosciences Funding Rounds
Codiak Biosciences raised $2.5M in a Post-IPO Equity announced in Jul 2022.
2 months later, a Post-IPO Equity of $20.0M was announced in Sep 2022.
Codiak Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Codiak Biosciences Funding Compared to Other Biotechnology Startups
Codiak Biosciences' latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Codiak Biosciences in Biotechnology and San Francisco
Companies Similar to Codiak Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Codiak Biosciences Funding FAQs
What does Codiak Biosciences do?
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
How much funding has Codiak Biosciences raised?
Codiak Biosciences has raised $22.5M across 2 rounds on record. The most recent is a Post-IPO Equity of $20.0M announced in Sep 2022.
When did Codiak Biosciences last raise funding?
Codiak Biosciences' most recent funding round on record is a Post-IPO Equity of $20.0M, announced in Sep 2022.
Who founded Codiak Biosciences?
FundedIQ lists Raghu Kalluri (Founder) at Codiak Biosciences.
Who is the CEO of Codiak Biosciences?
Douglas E Williams is listed as CEO at Codiak Biosciences.
Where is Codiak Biosciences headquartered?
Codiak Biosciences is based in San Francisco, California, United States.
How many employees does Codiak Biosciences have?
Codiak Biosciences is in the 101-250 employee band.
How does Codiak Biosciences' funding compare to other Biotechnology startups?
Codiak Biosciences' latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Codiak Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Codiak Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.